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Hyperphosphataemia in Haemodialysis Patients
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Abstract. In order to avoid aluminium toxicity, calcium-
containing phosphate binders have been used increasingly.
Unfortunately, calcium carbonate and calcium citrate pro-
duce hypercalcaemia in a number of patients. New studies
have shown that calcium acetate is promising in that it
binds more phosphate than calcium carbonate at compar-
able doses. We tested calcium acetate in eight severely
hyperphosphataemic patients (2.25 + 0.08 mmol/1) on
maintenance haemodialysis over 5 months. Serum phos-
phate decreased to 1.86 ± 0.06 mmol/1, but at the cost of an
increase in serum calcium. However, the increment of
serum calcium was always less than the respective decrease
of serum phosphate, and hypercalcaemia—immediately
reversible after dose reduction—only occurred once in
two patients.
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Introduction
Recently, calcium-containing salts such as calcium car-
bonate [1,2] and calcium citrate [3] have been used increas-
ingly as phosphate binders in patients with chronic renal
failure. Unfortunately, their long-term administration
produces gastrointestinal side-effects and hypercalcaemia
in a number of patients [2,4]. In addition, citrate enhances
gastrointestinal aluminium absorption in patients treated
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simultaneously with aluminium compounds, thereby
increasing the risk of severe aluminium toxicity [5].
Recent investigations have shown that calcium acetate,
administered in equivalent doses in a one-meal gastro-
intestinal balance study to healthy subjects [6] and to
haemodialysis patients [7], is equal to aluminium salts, but
more efficient than calcium carbonate in its phosphate-
binding capacity. This study reports on the long-term
effects of calcium acetate in haemodialysis patients with
severe hyperphosphataemia.
Patients and Methods
A newly available calcium acetate preparation (provided
by Grosse Apotheke, Dr G. Bichsel, CH-3800 Interlaken,
Switzerland) was studied. We selected eight maintenance
haemodialysis patients (five men, three women, age 23-64
years) with serum phosphate > 2.0 mmol/1, hypo- or
normocalcaemia, and imperfect compliance with
recommended dietary guidelines. They had been on
thrice-weekly haemodialysis, either 3 x 3 h (four cases) or
3 x 2.5 h (four cases), for a period of 4-35 months. A
Fresenius F-60 dialyser was used, the dialysate was
acetate buffered, and dialysate calcium was 1.625 mmol/1.
Previously, four patients had required aluminium
hydroxide (3 x 400 or 3 x 800 mg daily), three were on
calcium carbonate (3 x 1360 mg calcium carbonate or a
total of 1632 mg Ca2+ daily), and one patient was taking
aluminium hydroxide (3 x 400 mg) as well as calcium car-
bonate (3 x 340 mg). In all patients previous phosphate
binders were replaced by equivalent doses of calcium ace-
tate according to Sheikh et al [6], i.e. a total binder dose of
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Calcium Acetate as Phosphate Binder
Table 1. Serum values before and 1, 3 and 5 months after conversion to calcium acetate (CaAc) treatment
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Serum calcium (mmol/l)
Ionised calcium (mmol/l)
Serum phosphate (mmol/l)
CaxP(mmol2/l2)
Alkaline phosphatase (IU/1)
Total protein (g/1)
Serum aluminium (umol/1)
calcium acetate
(n = 7)
2.26 + 0.08
1.19 + 0.05
2.25 ±0.08
5.03+0.23
78+13
71.5±2.5
0.64 ±0.08
On calcium acetate treatment for
1 month
(n = 7)
2.37 + 0.08*
1.25 + 0.052
1.83±0.123
4.29±0.232
68 + 8
72.0 + 2.5
ND
3 months
("=6)
2.37 + 0.082
1.26 +0.08'
1.84 + 0.172
4.27+ 0.182
71+9
71.0 + 2.0
ND
5 months
(i=6)
2.44 + 0.131
1.26 + 0.08'
I.86 + 0.063
4.51+0.20'
72 + 6
72.0 + 3.0
0.34 + 0.07'
Ca x P, serum total calcium x phosphate product
'/><0.05; 2/><0.025;3P<0.01; */"<0.005 vs value before CaAc treatment; ND, not determined
50 mEq of calcium or aluminium corresponds to 4.33 g of
calcium acetate. Calcium acetate was provided in gelatine
capsules (400 mg of calcium acetate or 92.4 mg Ca2 + per
capsule) and given in divided doses immediately before
and after meals [8]. Informed consent was obtained from
all study participants.
Before entering the study and at monthly intervals there-
after, serum total calcium, ionised calcium, phosphate,
total protein, urea, creatinine, and alkaline phosphatase
were measured. Serum aluminium was determined in all
patients at the beginning, and in those previously exposed
to aluminium hydroxide at the end of the study. Whenever
serum phosphate increased, so did calcium acetate; if
hypercalcaemia (total calcium > 2.62 mmol/l) occurred,
the dose was reduced.
Therapeutic compliance was estimated once weekly by
the same physician (BH). Normalised protein catabolic
rate [9] was determined monthly. If dietary habits
changed, e.g. patients consumed snacks or sandwiches in
between regular meals, calcium acetate prescription was
adjusted individually.
Serum total calcium, phosphate, total protein, urea,
creatinine and alkaline phopsphatase were analysed using
standard laboratory techniques. Ionised calcium was
measured in whole blood by an ion-selective electrode.
Serum aluminium was determined by atomic absorption
spectroscopy. All results are expressed as mean + SEM.
The statistical analysis used Student's t test for paired
data.
. Results
Calcium acetate was generally well tolerated. The
patients' main complaint was the large number of cap-
sules, 18.4 ± 1.7, to be ingested daily; the mean prescribed
dose of calcium acetate was 7.36 + 0.68 g/day, or
1693 ± 156 mg of Ca2 + daily (range 1104-1932 mg/day).
No side-effects were noted except diarrhoea in one patient
who ended the study prematurely and was not taken into
account for further statistical analysis. A second patient
finished the protocol after 2.5 months when he received a
renal allograft.
Nutritional state did not change during the study, as
determined by weight after haemodialysis (65.8 ±3.6 kg
vs 65.3 + 4.4 kg before and at the end of the study, respect-
ively) and by protein catabolic rate (1.01 ±0.09g/kg per
day vs 1.15 ± 0.08 g/kg per day).
Table 1 summarises the serum measurements. Mean
serum calcium increased significantly, but the increase
from baseline at any time during the study was almost
always less than the corresponding decrease in serum
phosphate (Fig. 1); thus, the calcium x phosphate product
was reduced throughout the whole study period.
Hypercalcaemia of 2.82 and 2.75 mmol/l respectively,
occurred on one occasion in two patients after 2 and 5
months of treatment, respectively, and was reversible
after dose reduction. In one patient, reduced calcium ace-
tate intake provoked an increase in serum phosphate from
1.69 to 2.03 mmol/l.
Discussion
Our main finding is that replacing calcium carbonate or
aluminium hydroxyde by equivalent doses of calcium ace-
tate for 5 months improves the control of severe hyper-
phosphataemia in haemodialysis patients. These results
are in accordance with recent short-term studies, where
calcium acetate was shown to be equal to aluminium
hydroxide but superior to calcium carbonate in its
phosphate-binding capacity [6,7]. Given this greater
phosphate-binding: calcium-absorption ratio of calcium
acetate compared to calcium carbonate, the decrease in
serum phosphate to a larger extent than the respective
serum calcium increase in almost all our patients (Fig. I)
as well as the low frequency of hypercalcaemia (only one
episode in two patients) were to be expected. Similar
results have recently been presented [10].
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Fig. 1. Correlation between increase of serum calcium (+ACa) and fall
in serum phosphate ( — AP). Plot of all individual changes of serum Ca
and P levels from baseline values after 1, 3 and S months of CaAc
administration. Individual points, with one exception, always lie above
the line of identity, indicating that P decreases to a greater extent than
the corresponding increase of Ca.
Our study, however, does not firmly establish the
superiority of calcium acetate to calcium carbonate in a
long-term regimen, since we did not compare the two
compounds in a controlled manner. An average daily dose
of 2.5 g of calcium carbonate, or 1000 mg of Ca2 +/day,
clearly below the 1693 mg of Ca2+/day in this study, was
administered for 3 months to considerably less hyper-
phosphataemic dialysis patients by Williams et al [2].
Nevertheless, average serum calcium increased by
0.14 mmol/l, compared to 0.11 mmol/l after 3 months in
our patients, and calcium x phosphate products did not
decrease [2], as in our study. This might be taken as
indirect evidence for the greater treatment efficacy of
calcium acetate in a long-term regimen.
In conclusion, treatment with calcium acetate for 5
months is well tolerated and efficient in reducing severe
hyperphosphataemia in haemodialysis patients. Con-
trolled trials in a larger group of patients, however, will
be needed in order to define whether calcium acetate is
superior to calcium carbonate also in a long-term regimen,
and whether the general use of calcium acetate might be
recommended to all normo- and hypocalcaemic patients
with chronic renal failure and hyperphosphataemia.
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